Related Experiment Video
Updated: Aug 19, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Non-interventional cardiologists' perspectives on the role of pharmacogenomic testing in cardiovascular medicine
Kimberly M Deininger1, Robert L Page2, Yee Ming Lee2
1Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, CO, USA.
Aim:
To evaluate factors influencing cardiologists' perspectives about pharmacogenomic (PGx) testing in clinical practice.
Patients & Methods:
Semistructured interviews with practicing cardiologists were qualitatively analyzed to identify common themes.
Results:
Five themes were identified among 16 cardiologists from four specialties (n = 5 general cardiology, n = 3 electrophysiology, n = 2 adult congenital and n = 6 heart failure/transplant): cardiologists' knowledge and needs, perceived clinical validity and utility of PGx testing, dissemination and management of PGx results, patient-related considerations and incidental findings.
Conclusion:
Lack of evidence was considered by many cardiologists to be a major barrier hindering the use of PGx testing. However, they would consider adopting PGx if they were provided additional education, ongoing support and evidence supporting the clinical utility of PGx testing in cardiovascular medicine.
Related Concept Videos
Pharmacogenetics and Pharmacogenomics: Overview
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Pharmacogenomics: Identification of New Drug Targets

